Analysts have been eager to weigh in on the Technology sector with new ratings on Allscripts (MDRX – Research Report), Angi (ANGI – Research Report) and Axon Enterprise (AXON – Research Report).
Allscripts (MDRX)
J.P. Morgan analyst Anne Samuel maintained a Sell rating on Allscripts yesterday and set a price target of $19.00. The company’s shares closed last Wednesday at $17.60.
According to TipRanks.com, Samuel is a 4-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Allscripts with a $20.60 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Angi (ANGI)
J.P. Morgan analyst Cory Carpenter maintained a Buy rating on Angi yesterday and set a price target of $9.00. The company’s shares closed last Wednesday at $5.20, close to its 52-week low of $3.47.
According to TipRanks.com, Carpenter has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Angi with a $8.90 average price target, representing a 52.4% upside. In a report released yesterday, Wells Fargo also maintained a Buy rating on the stock with a $9.00 price target.
Axon Enterprise (AXON)
In a report released yesterday, Paul J Chung from J.P. Morgan maintained a Buy rating on Axon Enterprise, with a price target of $137.00. The company’s shares closed last Wednesday at $126.07.
According to TipRanks.com, Chung is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Axon Enterprise with a $143.00 average price target, a 19.7% upside from current levels. In a report released yesterday, Credit Suisse also maintained a Buy rating on the stock with a $142.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MDRX:
- J.P. Morgan Remains a Hold on Terns Pharmaceuticals (TERN)
- J.P. Morgan Keeps Their Hold Rating on Morphosys Ag (MOR)
- J.P. Morgan Reaffirms Their Buy Rating on IQVIA Holdings (IQV)
- J.P. Morgan Reaffirms Their Hold Rating on Tyson Foods (TSN)
- J.P. Morgan Keeps Their Buy Rating on Sarepta Therapeutics (SRPT)
